Home » Stocks » UROV

Urovant Sciences Ltd. (UROV)

Stock Price: $7.39 USD -0.30 (-3.90%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 230.43M
Revenue (ttm) n/a
Net Income (ttm) -148.75M
Shares Out 31.18M
EPS (ttm) -4.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $7.39
Previous Close $7.69
Change ($) -0.30
Change (%) -3.90%
Day's Open 7.70
Day's Range 7.22 - 7.84
Day's Volume 65,736
52-Week Range 6.55 - 15.98

More Stats

Market Cap 230.43M
Enterprise Value 299.70M
Earnings Date (est) Nov 2, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.18M
Float 6.27M
EPS (basic) -4.88
EPS (diluted) -4.88
FCF / Share -3.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 851,437
Short Ratio 12.08
Short % of Float 13.59%
Beta 1.24
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 14.26
Revenue n/a
Operating Income -140.34M
Net Income -148.75M
Free Cash Flow -110.97M
Net Cash -69.27M
Net Cash / Share -2.22
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -113.43%
ROE -1,750.72%
ROIC -176.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(215.70% upside)
Current: $7.39
Target: 23.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-139-111-37.00-27.06
Net Income-147-111-37.07-26.97
Shares Outstanding30.4225.1517.122.67
Earnings Per Share-4.82-4.43-2.16-10.10
Operating Cash Flow-102-109-34.09-25.26
Capital Expenditures-0.77-0.59-0.52-
Free Cash Flow-103-110-34.61-25.26
Cash & Equivalents51.6685.607.194.77
Total Debt90.6913.53--
Net Cash / Debt-39.0372.067.194.77
Book Value-58.0174.777.073.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Urovant Sciences Ltd.
Country United Kingdom
Employees 70
CEO James A. Robinson

Stock Information

Ticker Symbol UROV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: UROV
IPO Date September 27, 2018


Urovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.